GLAXF — GSK plc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1131399 ·
United Kingdom
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 8,887,000,000 | 6,497,000,000 | 2,127,000,000 | 1,543,000,000 | 71,699,000,000 | 2,934,000,000 | 53,337,000,000 |
| Jun 2026 | 8,409,000,000 | 6,143,000,000 | 481,000,000 | 435,000,000 | 61,738,000,000 | 3,105,000,000 | 44,561,000,000 |
| Mar 2026 | 7,629,000,000 | 5,754,000,000 | 2,293,000,000 | 1,737,000,000 | 62,869,000,000 | 3,442,000,000 | 45,447,000,000 |
| Dec 2025 | 8,618,000,000 | 5,961,000,000 | 1,506,000,000 | 636,000,000 | 61,118,000,000 | 3,150,000,000 | 45,162,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$8,918,000,000
Investing CF
$-10,896,000,000
Financing CF
$1,937,000,000
CapEx
$-2,654,000,000
Dividends Paid
$-2,698,000,000
Buybacks
$-886,000,000
EPS Diluted TTM
$1.07
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$12,458,000,000
Inventory
$6,300,000,000
Receivables
—
ST Investments
$28,000,000
EBIT TTM
$6,125,000,000
Pretax Income TTM
$5,383,000,000
Interest Exp TTM
$742,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$33,202,999,296
EBITDA
$10,817,999,872
Free Cash Flow
$3,482,625,024
Enterprise Value
$110,887,002,112
Total Cash
$3,105,999,872
Total Debt
$18,293,000,192
Shares Out
4,005,611,246
Trailing EPS
$1.60
Book Value
$5.95
ROE
33.4%
ROA
10.0%
Div Yield
3.82%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 32,667,000,000 | 8,338,000,000 | 5,716,000,000 | 61,100,000,000 | 45,162,000,000 | 16,377,000,000 | 7,741,000,000 |
| Dec 2024 | 31,376,000,000 | 5,542,000,000 | 2,575,000,000 | 59,500,000,000 | 46,377,000,000 | 13,671,000,000 | 6,554,000,000 |
| Dec 2023 | 30,328,000,000 | 7,345,000,000 | 4,928,000,000 | 59,000,000,000 | 46,200,000,000 | 13,347,000,000 | 6,768,000,000 |
| Dec 2022 | 29,324,000,000 | 6,729,000,000 | 14,956,000,000 | 60,100,000,000 | 50,050,000,000 | 10,598,000,000 | 7,403,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
What Does GSK (LSE:GSK) FDA Lung Cancer Approval Change For Investors?
2026-11-19 06:12 · Yahoo
Former Novartis U.S. Chief Strategy Officer Scott Howell, MD, MBA, Joins GOA Therapeutics as Chief Commercial Officer
2026-11-18 18:30 · Yahoo
GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer
2026-11-18 15:35 · Yahoo
GSK CFO Points to Cancer Drugs to Bridge £3.4 Billion Sales Forecast Gap
2026-11-18 02:12 · Yahoo
Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer
2026-11-17 22:00 · Yahoo
GSK wins FDA approval for lung cancer drug Nelkarmi
2026-11-17 19:18 · Yahoo
GSK Targets £40 Billion in Sales as HIV Patent Cliff Looms
2026-11-17 10:12 · Yahoo
Ziphius, a leading saRNA biotech, today announces the appointment of Mr. Antoon Loomans to its Board of Directors
2026-11-16 13:45 · Yahoo
GSK (LSE:GSK) Is Grappling With Suspected Counterfeit Antibiotics In Nigeria
2026-11-16 03:12 · Yahoo
Cigarette Sales Keep Falling. These 2 Tobacco Stocks Still Pay 5.5% Dividends
2026-11-14 16:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.